Otsuka Holdings and Otsuka Medical Devices have agreed to purchase the remaining interest in ReCor Medical from France-based venture capitalist Sofinnova Partners.

ReCor intends to continue to develop the Paradise System, a new therapeutic system for patients with hypertension, and explore its use in clinical applications such as heart failure, renal disease and other metabolic disorders following the acquisition.

Additionally, Recor plans to build Otsuka Medical Devices’ incubation and clinical development centre in the US and Europe.

The transaction is subject to the approval of ReCor’s shareholders.

Based in Japan, Otsuka Holding is a pharmaceutical company involved in the purchase and sale of pharmaceutical products, while Otsuka Medical Devices, also based in Japan, is focused on research and development of medical devices.

ReCor Medical is a US-based medical device company.

BioIVT has completed the acquisition of Optivia Biotechnology and the latter’s portfolio of transporter assays and molecular transport research solutions.

Based in the US, BioIVT is a provider of research models for the development of drugs, while Optivia Biotechnology, also based in the US, is a provider of transporter assay products.

“BioIVT has completed the acquisition of Optivia Biotechnology and the latter’s portfolio of transporter assays and molecular transport research solutions.”

The acquisition will strengthen the transporter sciences capabilities of the acquirer company and enable it to partner with customers on new drug applications.

Taisho Pharmaceutical (Taisho) has agreed to purchase an additional 7.06% interest in Duoc Hau Giang Pharmaceutical JSC (DHG Pharma) for an undisclosed sum.

The transaction will increase Taisho’s interest in DHG Pharma from 24.5% to 32%, pursuant to the completion of the transaction.

Based in Japan, Taisho is a pharmaceutical company that provides over-the-counter (OTC) medicines, while DHG Pharma is a Vietnam-based pharmaceutical company involved in the manufacture of dietary supplements and cosmetics.

BioCryst Pharmaceuticals has terminated the previously announced merger agreement with Idera Pharmaceuticals as the former failed to acquire approval from the stockholders for the merger.

The original merger agreement, signed in January this year, aimed to combine the businesses of the two companies for the development of drugs indicated for the treatment of rare diseases. BioCryst agreed to pay $6m to Idera for transaction-related charges as part of the agreement.

BioCryst Pharmaceuticals is a pharmaceutical company involved in the development of innovative medicines for rare conditions, while Idera Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of therapeutics for oncology and rare diseases.

Both companies involved in the transaction are based in the US.